“This role is a key initiative that arose in the campus strategic plan and has greatly expanded the reach of our research and development and enriched our medical school research enterprise,” said Chancellor Michael F. Collins.
Mr. Glasheen most recently served as a general partner in the venture capital fund Technology Partners. He has been an investor and/or board member in numerous companies, including Cadence Pharmaceuticals, Revance Therapeutics, Iomai and Incline Therapeutics.
Mr. Glasheen is also co-founder and co-chairman of ConsumerMed, a nonprofit organization focused on patient-centered health. He has also worked within the pharmaceuticals and medical products practice at McKinsey and Co.
Dr. Glasheen succeeds Brendan O’Leary, PhD, UMass Medical’s founding executive vice chancellor for innovation and business development.
More articles on executive moves:
Saint Francis Hospital-Memphis names new chief nursing officer: 3 takeaways
Prairie Lakes Healthcare System CEO announces retirement plans
18 latest hospital, health system executive moves
